Drug intelligence / Profile preview

sofosbuvir + velpatasvir + ribavirin

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral

Overview

A powerful antiviral regimen used primarily for treating chronic hepatitis C virus (HCV) infection. This combination therapy includes sofosbuvir (a nucleotide analog inhibiting NS5B polymerase), velpatasvir (targeting the NS5A protein), and ribavirin (a broad-spectrum antiviral that enhances efficacy). The regimen is particularly effective for treating HCV genotypes 1-6, with high efficacy rates (95-99% SVR) in patients with or without cirrhosis, and is valuable for those with decompensated cirrhosis or who have failed previous direct-acting antiviral therapies.

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on sofosbuvir + velpatasvir + ribavirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sofosbuvir + velpatasvir + ribavirin.

Explore the full profile